Alnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designation
BIO Elects John Maraganore, Ph.D., as New Chair
Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.